Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eliquis

Bristol-Myers Squibb (BMS) building

SMC gives green light for BMS’ Opdivo

Scotland will be first UK country to access the drug after NICE refusal

Bristol-Myers Squibb (BMS) building

Bristol-Myers Squibb acquires Cormorant for $520m

Deal with Swedish firm will boost BMS' oncology pipeline

Bristol-Myers Squibb (BMS) building

NICE ‘no’ for Opdivo in kidney cancer

BMS oncology drug knocked-back in draft guidance

Bristol-Myers Squibb (BMS) building

BMS to explore new options for its immuno-oncology drug Opdivo

Partners with PsiOxis to research its use with enadenotucirev

- PMLiVE

Merck & Co signs cancer vaccines research deal for Keytruda

Will work on range of personalised vaccines to complement its blockbuster

- PMLiVE

BMS appoints Murdo Gordon as chief commercial officer

He also becomes executive vice president

Bristol-Myers Squibb (BMS) building

Speedy NICE appraisal backs BMS’ Opdivo/Yervoy combination

But HTA body doesn't find Roche's Cotellic/Zelboraf cost-effective

- PMLiVE

Trial backs Keytruda use first-line in lung cancer

Suggests Merck & Co’s drug is more effective than chemotherapy for NSCLC patients

- PMLiVE

Updated EMPA-REG data show Jardiance also protects kidney

Boehringer Ingelheim and Lilly’s drug is the first to show positive impact on kidney damage

Roche Basel Switzerland

Roche’s Tecentriq works as first-line bladder cancer therapy

New trial data presented at ASCO supports wider use of the drug

Roche Basel Switzerland

Roche gets first approval for PD-L1 inhibitor Tecentriq

Expects to launch bladder cancer treatment within the next two weeks

National Institute for Health and Care Excellence NICE logo

NICE rejects Opdivo for lung cancer once again

Says PD-1 inhibitor is too expensive to be used routinely

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links